CD44-targeted N-benzyltetrahydroisoquinoline derivatives as anticancer agents with high tumor-to-normal cell selectivity

Colaboración

Año: 2025

Romero-Tamudo, S; Carrión, MD; Chayah, M; Espejo-Román, JM; Domene, C; Sánchez-Martin, RM; Cruz-López, O; Conejo-Garcia, A

Título: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

• Q1